- Male or female Chinese subjects, ages ≥18 at screening
- Subjects with symptoms of neuropathic pain associated with postherpetic neuralgia
(PHN). Subjects must have pain present for ﹥3 months after healing of the acute herpes
zoster skin rash
- At screening (V1), subjects must have a score ≥40mm on the 100-mm visual analog scale
(VAS) of the Short Form-McGill Pain Questionnaire (SF-MPQ, see Appendix 3)
- At randomization (V2), subjects must have a score ≥40mm on the 100-mm visual analog
scale (VAS) of the Short Form-McGill Pain Questionnaire (SF-MPQ, see Appendix 3)
- At randomization (V2), subjects must have completed at least 5 daily pain diaries
(DPRS, see Appendix 2) and have an average daily pain score ≥4 over the past 7 days
- Subjects who demonstrate a high response to placebo, with 30% decrease on the Pain
Visual Analog Scale (VAS) at randomization as compared to screening
- Subjects who have a high variability in pain scores during the 1 week screening
period, with any difference between two scores ?3